To evaluate the Safety and efficacy of Unani formulations in the treatment of Hyperacidity

Validation of Unani Pharmacopoeial formulation in Kasrat- e- Ratubat-e-Hamoozi (Hyperacidity)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/10/004116

Enrollment

300

Registered

2013-10-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K290- Acute gastritis Health Condition 2: null- hyperacidity

Interventions

Intervention1: 1. Jawarish Amla 2. Habb e Papita: 1. Jawarish Amla will be given in 10 gm twice daily at morning and evening with water. 2. Habb e Papita will be given twice after meals with water C

Eligibility

Inclusion criteria

Inclusion criteria: • Subjects in the Age group of 18-60 years • Subjects of both sexes • Subjects presenting with the following symptoms : o Retrosternal burning o Epigastric pain with retrosternal heaviness o Acidic brash o Anorexia o Nausea o Vomiting o Pain relieved after vomiting

Exclusion criteria

Exclusion criteria: • Duodenal ulcer • Peptic ulcer • H/o previous gastric surgery • Presence of cardiac & lung diseases • Pregnancy/lactation • Alcoholism • Diabetes • Stomach carcinoma • Crohnâ??s Diseases • Allergy/Intolerance to any ingredients of the drug1,9,12. • Zollinger Ellison Syndrome

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptomsTimepoint: 6 WEEKS	—

Secondary

Measure	Time frame
Outcome TimePoints Hematological and biochemical assessments for safety Timepoint: 6 WEEKS	—

Countries

India

Contacts

Public ContactDr Abdul Hannan

Central Council for Research in Unani Medicine (CCRUM),

ccrum605@gmail.com01128521981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026